# BioNTech warns of write-off of up to 900 million euros on COVID vaccine
Author: Pal sinha, Barnali
Author URL: https://startupobserver.com/author/pal-sinha-barnali/
Published: 2023-10-16
Category: Headlines
Category URL: https://startupobserver.com/category/headlines/
Meta Title: BioNTech flags up to 900 million euro vaccine write-off impact
Meta Description: Shares in BioNTech fell after it flagged write-downs reflecting Pfizer charges on their COVID-19 vaccine business, impacting 2023 revenue.
URL: https://startupobserver.com/biontech-warns-of-write-off-of-up-to-900-million-euros-on-covid-vaccine/

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qsrmdo0032wirgrt84jr62/images/2023-10-16t075900z1lynxmpej9f0a6rtroptp4health-coronavirus-1737044437830-compressed.jpg)

BERLIN (Reuters) – Shares in Germany’s BioNTech fell on Monday after it flagged write-downs of up to 900 million euros ($947 million) reflecting similar charges its partner Pfizer announced on their COVID-19 vaccine business last week.

Hit by a plunge in use of pandemic-related products, Pfizer on Friday said it would take $900 million in write-offs and other charges for their jointly developed Comirnaty vaccine, on top of much larger write-offs on Pfizer’s own COVID treatment Paxlovid.

For its third-quarter accounts, BioNTech will likely “recognise the effect of Pfizer’s inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech’s half of the gross profit-sharing agreement with Pfizer,” it said in a statement.

Shares in the vaccine maker, which is also developing cancer treatments, were down 7% to a two-month low in Frankfurt as of 0756 GMT.

BioNTech, which relies on vaccine-related profit-sharing payments from its U.S. partner for much of its revenue, said the write-offs would also reduce its 2023 revenue.

A BioNTech spokesperson on Monday declined to comment on the company’s current 2023 outlook, which is for COVID-19 vaccine revenue of about 5 billion euros.

The company is scheduled to release detailed third-quarter figures on Nov. 6.

The company added that it had been told by Pfizer that most of the write-offs relate to raw materials, as well as to inventories of vaccine versions that are older than the upgraded one currently in use.

($1 = 0.9498 euros)

(Reporting by Ludwig Burger and Rachel More; editing by Miranda Murray and Jason Neely)


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---